Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033726468> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2033726468 endingPage "e498" @default.
- W2033726468 startingPage "e487" @default.
- W2033726468 abstract "To comparatively analyze the efficacy, acceptability, and tolerability of various augmentation agents in adult patients with treatment-resistant depression.An electronic literature search of PubMed, EMBASE, the Cochrane Library, Web of Science, EBSCO, PsycINFO, EAGLE, and NTIS for trials published up to December 2013 was conducted. Several clinical trial registry agencies and US Food and Drug Administration reports were also reviewed. No language, publication date, or publication status restrictions were imposed.Randomized controlled trials comparing 11 augmentation agents (aripiprazole, bupropion, buspirone, lamotrigine, lithium, methylphenidate, olanzapine, pindolol, quetiapine, risperidone, and thyroid hormone) with each other and with placebo for adult treatment-resistant depression were included.The proportion of patients who responded to treatment was defined as primary efficacy, and the proportion of all-cause discontinuation and side-effects discontinuation were respectively defined as acceptability and tolerability, which were assessed with odds ratios (ORs) and a Bayesian random-effects model with 95% credible intervals (CrIs).A total of 48 trials consisting of 6,654 participants were eligible. In terms of the primary efficacy, quetiapine (OR = 1.92; 95% CrI, 1.39-3.13), aripiprazole (OR = 1.85; 95% CrI, 1.27-2.27), thyroid hormone (OR = 1.84; 95% CrI, 1.06-3.56), and lithium (OR = 1.56; 95% CrI, 1.05-2.55) were significantly more effective than placebo. Sensitivity analyses indicated that efficacy estimates for aripiprazole and quetiapine were more robust than those for thyroid hormone and lithium. In terms of acceptability, no significant difference was found between active agents and placebo. In terms of tolerability, compared to placebo, quetiapine (OR = 3.85; 95% CrI, 1.92-8.33), olanzapine (OR = 3.36; 95% CrI, 1.60-8.61), aripiprazole (OR = 2.51; 95% CrI, 1.11-7.69), and lithium (OR = 2.30; 95% CrI, 1.04-6.03) were significantly less well tolerated.Quetiapine and aripiprazole appear to be the most robust evidence-based options for augmentation therapy in patients with treatment-resistant depression, but clinicians should interpret these findings cautiously in light of the evidence of potential treatment-related side effects." @default.
- W2033726468 created "2016-06-24" @default.
- W2033726468 creator A5002098877 @default.
- W2033726468 creator A5008643568 @default.
- W2033726468 creator A5022694312 @default.
- W2033726468 creator A5041397944 @default.
- W2033726468 creator A5052663273 @default.
- W2033726468 creator A5063885814 @default.
- W2033726468 creator A5065261631 @default.
- W2033726468 creator A5072619665 @default.
- W2033726468 creator A5073216448 @default.
- W2033726468 creator A5077719963 @default.
- W2033726468 date "2015-04-22" @default.
- W2033726468 modified "2023-10-10" @default.
- W2033726468 title "Comparative Efficacy, Acceptability, and Tolerability of Augmentation Agents in Treatment-Resistant Depression" @default.
- W2033726468 cites W1583327662 @default.
- W2033726468 cites W1965476565 @default.
- W2033726468 cites W2012655610 @default.
- W2033726468 cites W2032194434 @default.
- W2033726468 cites W2068124573 @default.
- W2033726468 cites W2158635242 @default.
- W2033726468 doi "https://doi.org/10.4088/jcp.14r09204" @default.
- W2033726468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25919841" @default.
- W2033726468 hasPublicationYear "2015" @default.
- W2033726468 type Work @default.
- W2033726468 sameAs 2033726468 @default.
- W2033726468 citedByCount "138" @default.
- W2033726468 countsByYear W20337264682015 @default.
- W2033726468 countsByYear W20337264682016 @default.
- W2033726468 countsByYear W20337264682017 @default.
- W2033726468 countsByYear W20337264682018 @default.
- W2033726468 countsByYear W20337264682019 @default.
- W2033726468 countsByYear W20337264682020 @default.
- W2033726468 countsByYear W20337264682021 @default.
- W2033726468 countsByYear W20337264682022 @default.
- W2033726468 countsByYear W20337264682023 @default.
- W2033726468 crossrefType "journal-article" @default.
- W2033726468 hasAuthorship W2033726468A5002098877 @default.
- W2033726468 hasAuthorship W2033726468A5008643568 @default.
- W2033726468 hasAuthorship W2033726468A5022694312 @default.
- W2033726468 hasAuthorship W2033726468A5041397944 @default.
- W2033726468 hasAuthorship W2033726468A5052663273 @default.
- W2033726468 hasAuthorship W2033726468A5063885814 @default.
- W2033726468 hasAuthorship W2033726468A5065261631 @default.
- W2033726468 hasAuthorship W2033726468A5072619665 @default.
- W2033726468 hasAuthorship W2033726468A5073216448 @default.
- W2033726468 hasAuthorship W2033726468A5077719963 @default.
- W2033726468 hasConcept C118552586 @default.
- W2033726468 hasConcept C126322002 @default.
- W2033726468 hasConcept C142724271 @default.
- W2033726468 hasConcept C197934379 @default.
- W2033726468 hasConcept C204787440 @default.
- W2033726468 hasConcept C27081682 @default.
- W2033726468 hasConcept C2776412080 @default.
- W2033726468 hasConcept C2776619155 @default.
- W2033726468 hasConcept C2778375690 @default.
- W2033726468 hasConcept C2778715236 @default.
- W2033726468 hasConcept C2780211496 @default.
- W2033726468 hasConcept C2780634440 @default.
- W2033726468 hasConcept C71924100 @default.
- W2033726468 hasConceptScore W2033726468C118552586 @default.
- W2033726468 hasConceptScore W2033726468C126322002 @default.
- W2033726468 hasConceptScore W2033726468C142724271 @default.
- W2033726468 hasConceptScore W2033726468C197934379 @default.
- W2033726468 hasConceptScore W2033726468C204787440 @default.
- W2033726468 hasConceptScore W2033726468C27081682 @default.
- W2033726468 hasConceptScore W2033726468C2776412080 @default.
- W2033726468 hasConceptScore W2033726468C2776619155 @default.
- W2033726468 hasConceptScore W2033726468C2778375690 @default.
- W2033726468 hasConceptScore W2033726468C2778715236 @default.
- W2033726468 hasConceptScore W2033726468C2780211496 @default.
- W2033726468 hasConceptScore W2033726468C2780634440 @default.
- W2033726468 hasConceptScore W2033726468C71924100 @default.
- W2033726468 hasIssue "04" @default.
- W2033726468 hasLocation W20337264681 @default.
- W2033726468 hasLocation W20337264682 @default.
- W2033726468 hasOpenAccess W2033726468 @default.
- W2033726468 hasPrimaryLocation W20337264681 @default.
- W2033726468 hasRelatedWork W1741020416 @default.
- W2033726468 hasRelatedWork W1983457070 @default.
- W2033726468 hasRelatedWork W1991475958 @default.
- W2033726468 hasRelatedWork W1998036667 @default.
- W2033726468 hasRelatedWork W2036774371 @default.
- W2033726468 hasRelatedWork W2040915057 @default.
- W2033726468 hasRelatedWork W2097648013 @default.
- W2033726468 hasRelatedWork W2156102114 @default.
- W2033726468 hasRelatedWork W2537702573 @default.
- W2033726468 hasRelatedWork W3138859651 @default.
- W2033726468 hasVolume "76" @default.
- W2033726468 isParatext "false" @default.
- W2033726468 isRetracted "false" @default.
- W2033726468 magId "2033726468" @default.
- W2033726468 workType "article" @default.